[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,226
  • Shares Outstanding, K 27,754
  • Annual Sales, $ 50 K
  • Annual Income, $ -45,930 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 0.97
  • Price/Sales 1,154.57
  • Price/Cash Flow N/A
  • Price/Book 2.72

Options Overview Details

View History
  • Implied Volatility 122.20% (-1.15%)
  • Historical Volatility 71.64%
  • IV Percentile 9%
  • IV Rank 5.30%
  • IV High 764.52% on 03/27/26
  • IV Low 86.24% on 08/18/25
  • Expected Move (DTE 4) 0.13 (5.93%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 25
  • Volume Avg (30-Day) 167
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,478
  • Open Int (30-Day) 4,692
  • Expected Range 2.02 to 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +249,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.61 +34.72%
on 07/24/26
2.20 -1.41%
on 08/14/26
+0.27 (+14.16%)
since 07/17/26
3-Month
1.20 +80.75%
on 06/11/26
2.20 -1.41%
on 08/14/26
+0.62 (+39.94%)
since 05/15/26
52-Week
1.09 +98.99%
on 03/31/26
2.58 -15.93%
on 08/18/25
-0.36 (-14.27%)
since 08/15/25

Most Recent Stories

More News
INmune Bio CEO to Speak at Maxim Growth Summit

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inmune Bio...

INMB : 2.13 (-1.84%)
OmniScience and INmune Bio Collaborate to Enhance Clinical Trial Decision-Making with Vivo GenAI Platform

OmniScience and INmune Bio partner to enhance decision-making in Alzheimer's clinical trials using Vivo's genAI-powered platform.Quiver AI SummaryOmniScience and INmune Bio have announced a partnership...

INMB : 2.13 (-1.84%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 1.7420 (-5.84%)
LLY : 1,184.14 (+0.34%)
INMB : 2.13 (-1.84%)
XBI : 159.65 (+1.42%)
BIIB : 209.36 (-0.22%)
SAVA : 2.38 (+12.26%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...

ANVS : 1.7420 (-5.84%)
LLY : 1,184.14 (+0.34%)
INMB : 2.13 (-1.84%)
XBI : 159.65 (+1.42%)
BIIB : 209.36 (-0.22%)
SAVA : 2.38 (+12.26%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 1.7420 (-5.84%)
LLY : 1,184.14 (+0.34%)
INMB : 2.13 (-1.84%)
XBI : 159.65 (+1.42%)
BIIB : 209.36 (-0.22%)
SAVA : 2.38 (+12.26%)

Business Summary

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing...

See More

Key Turning Points

3rd Resistance Point 2.39
2nd Resistance Point 2.30
1st Resistance Point 2.23
Last Price 2.13
1st Support Level 2.07
2nd Support Level 1.98
3rd Support Level 1.91

See More

52-Week High 2.58
Last Price 2.13
Fibonacci 61.8% 2.01
Fibonacci 50% 1.84
Fibonacci 38.2% 1.66
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.